EICHORCondition: Advanced Cancer · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers
This description comes directly from the study's public registry record.
Qing Zhou, Doctor · 020-83827812 · zhouqing@gdph.org.cn
Always discuss trial participation with your own doctor first.
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center | Shenzhen, Guangdong, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
| The First Affiliated Hospital Of Nanchang University | Nanchang, Jiangxi, China | Not Yet Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi’an, Shanxi, China | Not Yet Recruiting |
| The First Affiliated Hospital of Xi'an Jiao Tong University | Xi’an, Shanxi, China | Not Yet Recruiting |
| Sichuan Cancer Hospital | Chengdu, Sichuan, China | Not Yet Recruiting |
| Mianyang Central Hospital | Mianyang, Sichuan, China | Not Yet Recruiting |
| Yunnan Cancer Hospital | Kunming, Yunnan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06662760